NMN

Quick Summary

NMN — β-nicotinamide mononucleotide — has become one of the most discussed longevity ingredients of the last five years. It is the immediate biosynthetic precursor to NAD+, a coenzyme central to cellular energy metabolism, DNA-repair signalling, and the activity of the sirtuin family of regulatory enzymes. The promise is easy to state: NAD+ concentrations decline measurably with age in human tissues, and orally administered NMN raises blood NAD+ to approximately twice baseline in human randomised controlled trials. The harder questions — which clinical endpoints respond, at what dose, with what safety profile, and inside which regulatory environment — are where careful reading matters. This page works through those questions in the neutral, citation-anchored style used by the NIH Office of Dietary Supplements fact sheets.

This sub-page is part of the NAD+ hub, which covers cross-precursor comparisons.

1. Where NMN Sits in the NAD+ Salvage Pathway

NMN is the direct substrate for NAD+ via NMNAT enzymes, one step below the rate-limiting NAMPT — and food sources (under 2 mg/kg) cannot reach the 250–1000 mg/day doses studied in RCTs.

NMN is a nucleotide built from nicotinamide, a ribose sugar, and a phosphate group. In mammalian cells it is the direct substrate for NMNAT1, NMNAT2, and NMNAT3 (the nicotinamide mononucleotide adenylyltransferases located in the nucleus, Golgi-cytoplasm, and mitochondrion respectively), which add an AMP unit to convert NMN into NAD+. The step immediately upstream of NMN is catalysed by NAMPT (nicotinamide phosphoribosyltransferase), widely viewed as the rate-limiting enzyme of the salvage pathway. NAMPT expression declines with age in several tissues.

NMN exists naturally in small amounts in foods such as edamame, broccoli, avocado, and tomato — but at concentrations under 2 mg per kilogram of fresh weight, far below the doses (250 to 1000 mg per day) at which human RCTs have observed approximately twofold elevation of blood NAD+. Dietary intake is therefore not a realistic alternative to supplementation if the goal is the pharmacological NAD+ elevation studied in trials.

Raising NAD+ has downstream consequences via the sirtuin family of NAD+-dependent deacetylases (SIRT1 through SIRT7), the PARP family of DNA-repair enzymes, and CD38, an immune-cell ecto-enzyme that consumes NAD+ at increasing rates with age. NMN supplementation has been studied as a way to refill the substrate side of that balance, with the major caveat that human evidence to date focuses on biochemical and functional surrogate endpoints rather than disease endpoints.

2. Mechanism Detail and the SLC12A8 Transporter Controversy

The prevailing model has oral NMN dephosphorylated to NR then re-converted intracellularly; the SLC12A8 direct-transport hypothesis is contested and unsupported as a basis for NMN-over-NR superiority.

How orally administered NMN gets from the gut into circulating blood, and then into cells, is more contested than the bare salvage-pathway diagram suggests. The prevailing model: in the small intestine, oral NMN is largely dephosphorylated by ectoenzymes such as CD73 and 5′-nucleotidase to yield nicotinamide riboside (NR); NR is then absorbed into enterocytes, rephosphorylated to NMN by nicotinamide riboside kinase 1 (NRK1), and only then converted by NMNAT enzymes to NAD+. Under this model, the in-vivo endpoints of oral NMN and oral NR converge considerably, because the molecules collapse to the same intracellular intermediate.

In 2019, Grozio and colleagues from the Imai laboratory published a high-profile paper in Nature Metabolism (PMID 31131364) proposing a different model: the transporter SLC12A8 as a mammalian-specific NMN transporter, allowing intact NMN to cross plasma membranes directly without dephosphorylation. This implied an absorptive route that NR could not share, and it became the mechanistic basis for many marketing claims about NMN being "superior" to NR. In 2020, Schmidt and Brenner (Iowa) published a rebuttal in the same journal (PMID 32694648) reporting that they could not reproduce the SLC12A8-mediated NMN transport phenomenon in their own cell models. Grozio and colleagues then published a reply (PMID 32694650) reaffirming their original observations. A same-period comment letter from Yoshida and colleagues (PMID 32694647) was published in the same exchange.

The current state of the field in 2026: the SLC12A8 hypothesis has not been widely independently replicated, and the prevailing mechanistic model remains the dephosphorylation-to-NR route. Statements that NMN absorption depends on SLC12A8 or that this confers superiority over NR are not supportable.

3. Human Clinical Evidence

The NMN human literature groups into three clusters: studies measuring the biochemical primary endpoint (blood NAD+) and safety; studies measuring functional secondary endpoints (insulin signalling, walking speed, grip strength, aerobic capacity, sleep, fatigue); and a small cluster on cardiovascular surrogate endpoints which has not yet reached statistical significance on its primary outcome.

4. Safety, Dosage, and Contraindications

Across all published RCTs adverse events are mild and placebo-indistinguishable; the most-studied chronic dose is 250 mg/day and validated short-term safety reaches 1250 mg/day for four weeks — beyond six months is unstudied.

The published RCTs collectively cover from a single 100 mg dose (Irie 2020) up to 1250 mg/day for four weeks (Fukamizu 2022). The most heavily studied chronic dose is 250 mg/day. The 600 to 1200 mg/day range was tested in Liao 2021 (athletics). The MIB-626 trial (Pencina 2023) used 1000 mg twice daily — 2000 mg/day total — for 14 days with no serious adverse events.

Across all published RCTs the most commonly reported adverse events are mild gastrointestinal disturbances and occasional headaches, in fewer than 5% of active-arm participants and at rates statistically indistinguishable from placebo.

Contraindications and open questions:

• Pregnancy and lactation: no human safety data; avoid.
• Children and adolescents under 18: no human safety data.
• Concurrent glucose-lowering medication: consult physician.
• PARP inhibitors and oncology medication: NAD+ is a substrate for PARP; oncology patients should not self-initiate NMN.
• Long-term safety beyond six months: no RCT has followed participants beyond several months.

4.1 Practical Dosing Notes (Educational Only)

The chronobiology finding (afternoon dosing outperformed morning dosing in older adults in Kim 2022 and Morita 2024) is one of the few timing-related signals in the supplement literature that has been replicated in independent trials.

5. NMN and the Sibling Precursors

NMN is part of a family of NAD+ precursors that includes nicotinamide riboside (NR), niacin (NA), nicotinamide (NAM), and dietary reduced NADH. Each has its own absorption route, enzymology, clinical trial portfolio, and safety profile. The frequent question — "Is NMN better than NR?" — has no defensible answer in the current human literature: no head-to-head RCT in humans has compared NMN and NR on a clinical endpoint.

Read the NAD+ Hub for the cross-precursor comparison. This NMN brief stays anchored in NMN-specific evidence.

One misconception worth correcting: some popular writing implies NMN is associated with Nobel Prize-winning aging research. The 2009 Nobel Prize in Physiology or Medicine was awarded to Blackburn, Greider, and Szostak for the discovery of how telomeres and telomerase protect chromosomes — work that is not about NMN, the salvage pathway, or sirtuins. Statements connecting NMN to a Nobel Prize are not factually supported.

6. Regulatory Status — United States · European Union · Brazil

NMN has one of the most asymmetric global regulatory profiles of any supplement ingredient. This page focuses on the three regulatory markets within the asxan.ai international scope.

6.1 United States — From 2022 IND Exclusion to 2025 Reversal

In late 2022, the FDA sent letters to NDI (New Dietary Ingredient) notifiers including SyncoZymes (NDIN 1247) and Inner Mongolia Kingdomway (NDIN 1259) stating that NMN was no longer eligible for inclusion in dietary supplements under 21 USC 321(ff)(3)(B)(ii), because Metro International Biotech had previously made NMN the subject of an Investigational New Drug application. In response, the Natural Products Association filed a citizen petition in March 2023, followed by a federal lawsuit in September 2024. On 29 September 2025, the FDA withdrew its 2022 IND exclusion determination, restoring NMN's legal status as a dietary supplement ingredient in the United States. On 2 December 2025, the FDA formally restored the NDI notification status of SyncoZymes and other notifiers.

Current US framework as of 2026: NDI notification under 21 CFR 190.6 must be submitted 75 days before marketing. The FDA does not "approve" supplements; absence of an objection letter is the operative regulatory signal. Labels must comply with 21 CFR Part 111 (cGMP), use the Supplement Facts panel, and carry the standard FDA disclaimer: "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." Only structure-function claims are permissible.

6.2 European Union — Novel Food Pending

NMN is regulated under Regulation (EU) 2015/2283 on Novel Foods. As of early 2026, no NMN product has received Novel Food authorisation. Six applications are in various stages of EFSA evaluation; the most advanced is EffePharm's Uthever (public consultation completed February 2025), with Shanghai Shangke Biotech's PC-1537 entering formal EFSA evaluation in July 2025. Until a Novel Food authorisation is granted, NMN cannot be lawfully marketed as a food or food supplement in the European Union.

6.3 Brazil — Full Prohibition Under ANVISA RE 1139/2022

Brazil is the strictest current market for NMN. On 7 April 2022, ANVISA published Resolução-RE nº 1139/2022, imposing a full-chain prohibition on NMN covering commercialisation, distribution, manufacture, importation, advertising, and use, including cross-border e-commerce. The resolution also mandated recall of any NMN-containing products already on the Brazilian market. Brazilian readers should treat this as unambiguous: NMN is not available in Brazil through any legal channel, including international e-commerce.

6.4 Summary of Regulatory Red Lines

7. Use Cases Across Goals and Lifestyles

7.1 For the longevity stack reader

NMN is the flagship NAD+ precursor in any longevity-oriented stack discussion and the precursor for which biochemical and functional human RCT evidence is most systematically developed. Yoshino 2021 and Pencina 2023 both showed approximately twofold elevation of blood or muscle NAD+; Yi 2022 established the dose-response from 300 to 900 mg/day; Igarashi 2022 demonstrated functional gain in older adults; the Zhang 2025 meta-analysis confirmed the NAD+ elevation across 12 trials. What the evidence does not support: that NMN extends human lifespan or reverses aging.

7.2 For the athletic performance reader and the athletic performance lifestyle

The Liao 2021 RCT (48 amateur runners; 6 weeks; 300/600/1200 mg/day) is the single strongest human signal for an athletic-performance endpoint to date. Higher-dose arms showed dose-dependent increases in VO2 max, ventilatory threshold, and skeletal-muscle oxygen utilisation. The cohort was amateur, not elite, and the trial ran six weeks. Generalising to elite or competitive athletes, or to longer training cycles, is not currently supported by direct evidence.

7.3 For the senior 60+ lifestyle

This is the lifestyle context where the NMN evidence base is densest. Three independent RCTs (Igarashi 2022, Kim 2022, Morita 2024) targeted older adult cohorts and reported functional improvements: walking speed (p = 0.033 in Igarashi), grip strength (p = 0.019 in Igarashi), five-times sit-to-stand (Kim afternoon arm), and sleep quality and self-reported fatigue (Kim afternoon arm; Morita PSQI total score). The chronobiology finding — afternoon dosing outperformed morning dosing in older adults in both Kim 2022 and Morita 2024 — is one of the most replicated timing-of-administration findings in the supplement literature.

7.4 For the cognitive support reader (mechanistic only)

Mechanistic interest rests on NAD+ in brain energy metabolism and sirtuin-mediated neuroprotective pathways in cellular and animal models. No published human RCT has measured a cognitive endpoint on NMN as a primary outcome. The cross-link to a cognitive-support goal is mechanistic adjacency — biologically plausible, not yet clinically demonstrated. Statements about "improving memory" or "enhancing cognition" are not supportable.

7.5 For the heart health reader (preliminary)

Katayoshi 2023 reported a trend toward reduced arterial stiffness (baPWV) at 250 mg/day for 12 weeks, with rises in NAD-related metabolites. The trend did not reach statistical significance — the cardiovascular evidence is currently hypothesis-generating only.

7.6 For the high-stress lifestyle (mechanistic)

The biological rationale rests on NAD+ in PARP-mediated DNA-damage repair and sirtuin-mediated regulation of the cellular stress response. No RCT has used "high stress" or "chronic stress" as a cohort criterion or outcome.

7.7 For the intermittent fasting lifestyle (mechanistic)

Intermittent fasting shares mechanistic territory with NMN-supported pathways (sirtuin activation, autophagy, mitochondrial biogenesis). No human RCT has tested NMN inside an intermittent-fasting cohort or measured fasting-specific outcomes.

8. Bottom Line

Supported by careful reading of the human evidence:

• Oral NMN at 250 to 1000 mg/day reliably raises blood NAD+ to approximately twice baseline in healthy adults across multiple RCTs.
• Functional improvements (walking speed, grip strength, aerobic capacity in amateur athletes, sleep quality and fatigue in older adults) are documented in well-conducted RCTs, with the afternoon-dosing chronobiology being one of the more reproducible findings.
• Short-term safety at doses up to 1250 mg/day for four weeks has been validated, with no serious adverse events reported across the studies reviewed here.

Not supported by current human evidence:

• NMN has not been shown to extend human lifespan or to reverse aging.
• NMN has not been shown to be superior to NR or any other NAD+ precursor; no head-to-head human RCT exists.
• NMN has no human evidence for treating or preventing disease.
• NMN has no human cognitive-endpoint evidence; the cognitive interest is mechanistic only.
• The SLC12A8 transporter mechanism is a contested hypothesis, not an established absorption route.

Related Goals and Lifestyles

Read the Evidence (deep dive long-form)

For deep-dive narrative on NAD⁺-axis precursor decisions (25-year clinical evidence chronology · NMN vs NR precursor decision tree · reduced NADH vs NMNH redox-form comparison), see the dedicated evidence articles:

• 25 Years of NAD⁺ Clinical Evidence — niacin → NMN/NR/NADH chronology · 30 PubMed-verified citations · Era 1-4 regulatory + RCT history · honest nulls + citation corrections.
• NMN vs NR Decision Tree — 5-dimension precursor decision tree (absorption / RCT pool / NAD⁺ elevation / regulatory / safety) · 21 PubMed-verified citations.
• Reduced NADH vs NMNH — redox-form comparison adjacent to the precursor decision · chemistry + history + comparison table · 17 PubMed-verified citations.

Cross-reading these three peer evidence articles alongside this NMN fact sheet builds the holistic NAD⁺-axis evidence picture from mechanism → RCT → precursor decision.

References

1. PMID 33888596 · Yoshino M et al. 2021 · Science · 250 mg/day × 10 weeks, 25 postmenopausal prediabetic women; muscle insulin signalling and muscle NAD+ metabolites.
2. PMID 36482258 · Yi L et al. 2022/2023 · GeroScience · dose-finding 300/600/900 mg/day × 60 d, n=80; dose-dependent NAD+ elevation.
3. PMID 35479740 · Okabe K et al. 2022 · Frontiers in Nutrition · 250 mg/day × 12 weeks, n=30; blood NAD+ approximately twofold by week 4.
4. PMID 36740954 · Pencina KM et al. 2023 · J Clin Endocrinol Metab · MIB-626 1000 mg BID × 14 d, n=32; blood NAD+ approximately twofold.
5. PMID 31685720 · Irie J et al. 2020 · Endocrine Journal · single-dose dose-escalation safety in 10 healthy Japanese men at 100/250/500 mg.
6. PMID 34238308 · Liao B et al. 2021 · J Int Soc Sports Nutr · 300/600/1200 mg/day × 6 weeks, 48 amateur runners; aerobic-capacity improvements.
7. PMID 35927255 · Igarashi M et al. 2022 · npj Aging · 250 mg/day × 12 weeks, 42 older Japanese men; walking speed p = 0.033, grip strength p = 0.019.
8. PMID 35215405 · Kim M et al. 2022 · Nutrients · 250 mg/day × 12 weeks, 108 older Japanese adults, morning vs afternoon; afternoon-arm improvements.
9. PMC 11336149 · Morita Y et al. 2024 · 250 mg/day × 12 weeks, 60 older adults; chronobiology reproduction.
10. PMID 36797393 · Katayoshi T et al. 2023 · Scientific Reports · 250 mg/day × 12 weeks, n=36; baPWV trend not statistically significant.
11. PMID 36002548 · Fukamizu Y et al. 2022 · Scientific Reports · 1250 mg/day × 4 weeks, n=20; no clinically significant abnormalities.
12. PMID 39531138 · Chen F et al. 2024 · Current Diabetes Reports · meta-analysis on glucose, insulin, lipid outcomes.
13. PMID 39116016 · Zhang J, Poon ET, Wong SH 2025 · Crit Rev Food Sci Nutr · meta-analysis of 12 NMN RCTs (n=513).
14. PMID 37619764 · Song Q et al. 2023 · Advances in Nutrition · update review of NMN human trials.
15. PMID 31131364 · Grozio A et al. 2019 · Nature Metabolism · SLC12A8 proposal.
16. PMID 32694648 · Schmidt MS, Brenner C 2020 · Nature Metabolism · SLC12A8 non-replication.
17. PMID 32694647 · Yoshida M et al. 2020 · same-period comment letter.
18. PMID 32694650 · Grozio A et al. 2020 reply to Schmidt and Brenner.

Educational Disclaimer

This page is educational reference content and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Discuss any supplement use with a qualified healthcare provider, particularly if you are pregnant or breastfeeding, take prescription medication, have a diagnosed condition, or are undergoing oncology, cardiology, or endocrinology treatment. Regulatory status varies by jurisdiction; in Brazil NMN is prohibited across the full supply chain under ANVISA RE 1139/2022.

Frequently Asked Questions

The questions below address the most commonly searched questions on NMN across general web search and AI assistants. Answers reference the evidence and regulatory framework cited throughout this page; they are intentionally concise.